Center of attention has moved to the newest working thing: management's energy is disproportionately on a small but alre
The model's full reasoning — Q3 2023 call → NOWe need to determine if management devotes a clearly disproportionate share of energy, enthusiasm, and detail to one identifiable part of the business that is still a minority of overall results, and that part is described as already producing real, current business, and is treated as the main driver. The transcript is about IceCure Medical, which has a product called ProSense, a cryoablation system. The company has various indications and markets. The call covers regulatory updates, commercial expansion, and financial results. Key points: The company is focused on ProSense for breast cancer, but also other indications. The FDA denied De Novo for breast cancer, and they filed an appeal. They have approvals in Brazil, Canada, etc. They have independent studies, commercial distribution expansion, and increased sales of ProSense systems and disposables. The financial results: ProSense systems and disposable probe sales increased 11% to $1.7 million for nine months, total revenue ~$2 million. So ProSense sales are the majority of revenue? Actually total revenue is $2 million, and ProSense systems and disposables are $1.7 million, so that's the bulk. The rest is from the Terumo distribution agreement which ended. So ProSense is the main product. But the question asks: Is there a part of the business that is still a minority of overall results, yet gets disproportionate attention? Possibly the breast cancer indication? Or the U.S. market? Or the appeal? Or the independent studies? Or the new distribution deals? Management spends a lot of time on the FDA appeal for breast cancer, and on the ICE3 trial, and on independent studies. But the company's overall business is ProSense across multiple indications. The breast cancer indication is a key target, but it's not yet approved in the U.S. However, they have approvals elsewhere. The revenue from ProSense is across all indications. So the breast cancer part is not necessarily a separate revenue stream; it's part of ProSense. The question asks: "ONE identifiable part of the business that is still a MINORITY of the company's overall results today" — meaning that part generates less revenue than the rest. What could that be? Possibly the U.S. market? Or the breast cancer indication? Or the new distribution in Portugal? Or the India first procedure? But these are not separate revenue streams.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| HUYA | HUYA Inc. | Q4 2023 | 2024-03-19 | C |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| APAM | Artisan Partners Asset Management Inc. | Q3 2023 | 2023-11-01 | C+ |
| ANGO | AngioDynamics, Inc. | Q1 2024 | 2023-10-04 | B |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| BLZE | Backblaze, Inc. | Q3 2022 | 2022-11-11 | D |
| PKX | POSCO Holdings Inc. | Q3 2022 | 2022-10-24 | D |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| ZENV | Zenvia Inc. | Q4 2021 | 2022-03-17 | C+ |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| SLQT | SelectQuote, Inc. | Q2 2022 | 2022-02-07 | F |
| ZH | Zhihu Inc. | Q3 2021 | 2021-11-22 | D |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| UFI | Unifi, Inc. | Q4 2021 | 2021-08-07 | B |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| MITK | Mitek Systems, Inc. | Q4 2017 | 2017-11-07 | C+ |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| NWSA | News Corporation | Q2 2016 | 2016-08-08 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
YMM · Q2 2022 → YESThe question is: Does management devote a clearly DISPROPORTIONATE share of its energy, enthusiasm, and detail to ONE identifiable part of the business that is still a MINORITY of the company's overal...YES The transcript shows management devoting a clear, extended spotlight to the commission/online transaction service (20%+ of revenue, minority share). They repeatedly highlight its strong performance, dynamic adjustments, user retention metrics, and role in driving monetization and future growth, framing it as a key driver for the company's trajectory while 347.8 million in commissions is already generating real revenue now. Other areas like overall GTV, fulfillment rates, and user MAUs receive routine coverage, but the commission piece gets the richest, most conviction-driven discussion.
PUMP · Q4 2023 → YESThe question is: Does management devote a clearly DISPROPORTIONATE share of its energy, enthusiasm, and detail to ONE identifiable part of the business that is still a MINORITY of the company's overal...YES The transcript shows management devoting a clearly disproportionate share of its prepared remarks and Q&A to the FORCE electric fleet offering (a new technology/service line). They describe it as minority today (only two fleets operating out of 14-15 active, with plans for three and four more), yet repeatedly highlight its real 2023 performance (on contract, strong results, efficient performance, customer satisfaction, diesel displacement), its unique positioning, and its role as the core driver of the company's future trajectory through fleet transition and industrialization.
NICE · Q4 2023 → YESThe question is: Does management devote a clearly DISPROPORTIONATE share of its energy, enthusiasm, and detail to ONE identifiable part of the business that is still a MINORITY of the company's overal...YES The transcript shows management devoting a clearly disproportionate share of its energy, enthusiasm, and detail to AI (Enlighten AI, Copilot, Autopilot) as the catalyst driving growth across CXone, digital engagement, platformization, and new solutions. This is framed as the overarching theme that will shape the 2024 trajectory and beyond. AI is described as already producing real, current business activity: 375% increase in Enlighten bookings in Q4, multiple seven-digit ACV deals won with AI features, and accelerating adoption among customers and prospects.